Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Peri-vascular Adipose Tissue Inflammation Evaluated Using Coronary CT Angiography (P-VECT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04181749
Recruitment Status : Not yet recruiting
First Posted : November 29, 2019
Last Update Posted : March 10, 2020
Sponsor:
Collaborators:
University of Oxford
British Heart Foundation
National Institute for Health Research, United Kingdom
Information provided by (Responsible Party):
University of Leicester

Brief Summary:
The P-VECT Study proposes to test the use of CCTA-derived FAI measurements in a group of patients with coronary artery inflammation, who will receive routinely-used statin and aspirin treatment. The P-VECT Study is a pilot study that will provide the rationale and data for power calculations to enable design of pivotal trials of the clinical effectiveness of FAI.

Condition or disease Intervention/treatment Phase
Cardiovascular Risk Factor Drug: aspirin and atorvastatin Phase 2

Detailed Description:
In this research we will study the ability of coronary CT angiography (CCTA)- derived Fat Attenuation Index (FAI) measurements to detect changes in coronary artery inflammation following treatment with atorvastatin and aspirin . CT scan images are used to evaluate the presence of atherosclerotic plaque in the wall of the coronary arteries. The new CCTA technique, FAI, detects and quantifies coronary artery inflammation by analysis of the characteristics of the adipose tissue (fat) around the wall of the artery - the peri-vascular adipose tissue (PVAT) This is a pilot study, involving patients undergoing a clinically indicated CCTA as part of their routine clinical care who are shown (on their scans) to have mild coronary artery plaques (<50% luminal stenosis) with a high FAI value (>70.1 HU). Patients will have 6 visits (one of which screening) with hospital attendance on 3 occasions for blood tests and drug supply. The pilot study will provide the rationale for power calculations from which further studies can be developed to evaluate the clinical effectiveness of FAI.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Patients randomized to No treatment or Aspirin and Statin
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Peri-vascular Adipose Tissue Inflammation Evaluated Using Coronary CT
Estimated Study Start Date : April 20, 2020
Estimated Primary Completion Date : October 31, 2022
Estimated Study Completion Date : January 20, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: No treatment
Patients will not be prescribed aspirin and statin
Active Comparator: Aspirin and Atorvastatin
Patients prescribed aspirin and atorvastatin
Drug: aspirin and atorvastatin
Patients will be randomized and prescribed either no treatment or aspirin 75mg and Atorvastatin 40mg




Primary Outcome Measures :
  1. Evaluate ability of new coronary CT angiogram (CCTA) scan biomarker- Fat Attenuation Index (FAI). [ Time Frame: 3year study- Two years recruitment with 8 month patient follow up ]
    The overall objective is to evaluate the ability of a new cardiac CCTA scan technique, fat attenuation index (FAI), to detect changes in coronary artery perivascular fat inflammation following 8 months treatment with atorvastatin and aspirin medication


Secondary Outcome Measures :
  1. Evaluate the association between changes in Fat Attenuation Index (FAI) and plasma lipid parameters. [ Time Frame: 3year study- Two years recruitment with 8 month patient follow up ]
    Evaluate this association by measuring the % of change in plasma LDL-c.

  2. Evaluate the association between changes in Fat Attenuation Index (FAI) and plasma lipid parameters. [ Time Frame: 3year study- Two years recruitment with 8 month patient follow up ]
    Evaluate this association by measuring the % of change in plasma HDL-c.

  3. Evaluate the association between changes in Fat Attenuation Index (FAI) and plasma lipid parameters. [ Time Frame: 3year study- Two years recruitment with 8 month patient follow up ]
    Evaluate this association by measuring the % of change in triglycerides.

  4. Evaluate the association between changes in FAI and plasma biomarkers of inflammation. [ Time Frame: 3year study- Two years recruitment with 8 month patient follow up ]
    Evaluate this association by measuring the % of change in plasma IL-6.

  5. Evaluate the association between changes in FAI and plasma biomarkers of inflammation. [ Time Frame: 3year study- Two years recruitment with 8 month patient follow up ]
    Evaluate this association by measuring the % of change in plasma high sensitivity C-reactive protein (hsCRP) .



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Participants must satisfy the following conditions:

  1. Male or Female, aged 30 to 80 years,
  2. CCTA scan showing mild coronary artery plaques (<50% luminal stenosis) with a high FAI value (>70.1 HU) within last 3 months.
  3. No definite clinical indication for statin treatment (i.e. do not have either cholesterol >6.5 mM, or cholesterol >5.0 mM and QRISK score >10%).
  4. Clinical equipoise for statin and aspirin treatment, as determined by the local treating physician. In these patients, there is clinical equipoise because routine treatment with aspirin and statin is not mandated by current guidelines, but the presence of minor coronary artery plaques is frequently interpreted by clinicians as an indication for aspirin and statin treatment. Accordingly, some patients in this group typically receive aspirin and statin treatment, whereas others do not.
  5. Willing and able (in the Investigators opinion) to comply with all study requirements.
  6. Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of any incidental findings.
  7. Able to understand both verbal or written English

    -

Exclusion Criteria:

  • The participant may not enter the study if ANY of the following are known to apply:

    1. Previous documented history of coronary artery disease requiring treatment. This includes any of the following:

      Acute myocardial infarction Unstable angina Coronary revascularization procedure Clinically significant coronary artery disease diagnosed by invasive or non-invasive testing.

    2. Known diabetes mellitus
    3. Definite clinical indication for statin treatment (i.e. has either cholesterol >6.5 mM, or cholesterol >5.0 mM and QRISK score >10%).
    4. Treatment with aspirin, statin or any prescribed lipid modification therapy in 6 weeks before baseline CCTA
    5. Atrial fibrillation (paroxysmal or persistent)
    6. History of New York Heart Association (NYHA) Class III or IV heart failure within the past 12 months of consent.
    7. Autoimmune disease requiring immunosuppressive therapy or systemic corticosteroid therapy
    8. Active treatment with any anti-inflammatory agents (e.g. NSAIDs, corticosteroids)
    9. Active neoplasm requiring surgery, chemotherapy, or radiation within the prior 12 months (subjects with a history of malignancy who have undergone curative resection or otherwise not requiring treatment for at least 12 months prior to screening with no detectable recurrence are allowed)
    10. Contraindication for aspirin and/or statin therapy
    11. Severe Chronic kidney disease (estimated glomerular filtration rate < 30 mL/min/1.73 m² and/or serum creatinine > 2.5 mg/dL or 220 µmol/l).
    12. Hepatic dysfunction (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] > 3 × the upper limit of normal [ULN] measured on local labs in last 6 months)
    13. Any clinically significant abnormality identified at the time of screening that, in the opinion of the Investigator, would preclude safe completion of the study.
    14. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
    15. Participants who have participated in another research study involving a treatment intervention or an investigational product, in the past 12 weeks.
    16. Patients unable to understand verbal or written English.
    17. Contraindication to contract dye for CCTA.
    18. Pregnancy
Layout table for additonal information
Responsible Party: University of Leicester
ClinicalTrials.gov Identifier: NCT04181749    
Other Study ID Numbers: 0719
First Posted: November 29, 2019    Key Record Dates
Last Update Posted: March 10, 2020
Last Verified: February 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Inflammation
Pathologic Processes
Aspirin
Atorvastatin
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors